within Pharmacolibrary.Drugs.ATC.N;

model N05CD15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05CD15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nimetazepam is a benzodiazepine derivative with hypnotic, sedative, and anxiolytic effects, originally used for the short-term management of severe insomnia and sometimes as an anxiolytic. It is considered a potent hypnotic, but is not approved for medical use in many countries today due to its potential for dependence and abuse.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults based on published data for structurally related benzodiazepines and limited public information on nimetazepam. No direct clinical PK study reference found.</p><h4>References</h4><ol><li><p>Yanagi, Y, et al., &amp; Kitagawa, S (1975). Comparative metabolic study of nimetazepam and its desmethyl derivative (nitrazepam) in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 5(4) 245–247. DOI:<a href=&quot;https://doi.org/10.3109/00498257509052071&quot;>10.3109/00498257509052071</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1154804/&quot;>https://pubmed.ncbi.nlm.nih.gov/1154804</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05CD15;
